TrialHealth and quality of life outcomes2013
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.
Vibeke Strand et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
28 papers cite it
this paperpooled ittrialcites it